Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021

被引:3
|
作者
Stoner, Marie C. D. [1 ]
Angulo, Frederick J. [2 ]
Rhea, Sarah [1 ,3 ]
Brown, Linda Morris [1 ]
Atwell, Jessica E. [2 ]
Nguyen, Jennifer L. [2 ]
McLaughlin, John M. [2 ]
Swerdlow, David L. [2 ]
MacDonald, Pia D. M. [1 ,4 ]
机构
[1] RTI Int, Res Triangle Pk, NC USA
[2] Pfizer Inc, Pfizer Vaccines, Med Dev Sci & Clin Affairs, Collegeville, PA USA
[3] North Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC USA
[4] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2022年 / 9卷 / 02期
关键词
COVID-19; vaccination; population immunity; SARS-CoV-2; NONMEDICAL VACCINE EXEMPTIONS; COVID-19; VACCINE; PERTUSSIS;
D O I
10.1093/ofid/ofab647
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Information is needed to monitor progress toward a level of population immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sufficient to disrupt viral transmission. We estimated the percentage of the US population with presumed immunity to SARS-CoV-2 due to vaccination, natural infection, or both as of August 26, 2021. Methods Publicly available data as of August 26, 2021, from the Centers for Disease Control and Prevention were used to calculate presumed population immunity by state. Seroprevalence data were used to estimate the percentage of the population previously infected with SARS-CoV-2, with adjustments for underreporting. Vaccination coverage data for both fully and partially vaccinated persons were used to calculate presumed immunity from vaccination. Finally, we estimated the percentage of the total population in each state with presumed immunity to SARS-CoV-2, with a sensitivity analysis to account for waning immunity, and compared these estimates with a range of population immunity thresholds. Results In our main analysis, which was the most optimistic scenario, presumed population immunity varied among states (43.1% to 70.6%), with 19 states with <= 60% of their population having been infected or vaccinated. Four states had presumed immunity greater than thresholds estimated to be sufficient to disrupt transmission of less infectious variants (67%), and none were greater than the threshold estimated for more infectious variants (>= 78%). Conclusions The United States remains a distance below the threshold sufficient to disrupt viral transmission, with some states remarkably low. As more infectious variants emerge, it is critical that vaccination efforts intensify across all states and ages for which the vaccines are approved.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Estimating unobserved SARS-CoV-2 infections in the United States
    Perkins, T. Alex
    Cavany, Sean M.
    Moore, Sean M.
    Oidtman, Rachel J.
    Lerch, Anita
    Poterek, Marya
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (36) : 22597 - 22602
  • [22] Substantial underestimation of SARS-CoV-2 infection in the United States
    Sean L. Wu
    Andrew N. Mertens
    Yoshika S. Crider
    Anna Nguyen
    Nolan N. Pokpongkiat
    Stephanie Djajadi
    Anmol Seth
    Michelle S. Hsiang
    John M. Colford
    Art Reingold
    Benjamin F. Arnold
    Alan Hubbard
    Jade Benjamin-Chung
    Nature Communications, 11
  • [23] SARS-CoV-2 Genomes From Oklahoma, United States
    Narayanan, Sai
    Ritchey, John C.
    Patil, Girish
    Narasaraju, Teluguakula
    More, Sunil
    Malayer, Jerry
    Saliki, Jeremiah
    Kaul, Anil
    Agarwal, Pratul K.
    Ramachandran, Akhilesh
    FRONTIERS IN GENETICS, 2021, 11
  • [24] Emergence of an early SARS-CoV-2 epidemic in the United States
    Zeller, Mark
    Gangavarapu, Karthik
    Anderson, Catelyn
    Smither, Allison R.
    Vanchiere, John A.
    Rose, Rebecca
    Snyder, Daniel J.
    Dudas, Gytis
    Watts, Alexander
    Matteson, Nathaniel L.
    Robles-Sikisaka, Refugio
    Marshall, Maximilian
    Feehan, Amy K.
    Sabino-Santos, Gilberto
    Bell-Kareem, Antoinette R.
    Hughes, Laura D.
    Alkuzweny, Manar
    Snarski, Patricia
    Garcia-Diaz Jr, Julia
    Scott, Rona S.
    Melnik, Lilia, I
    Klitting, Raphaelle
    McGraw, Michelle
    Belda-Ferre, Pedro
    DeHoff, Peter
    Sathe, Shashank
    Marotz, Clarisse
    Grubaugh, Nathan D.
    Nolan, David J.
    Drouin, Arnaud C.
    Genemaras, Kaylynn J.
    Chao, Karissa
    Topol, Sarah
    Spencer, Emily
    Nicholson, Laura
    Aigner, Stefan
    Yeo, Gene W.
    Farnaes, Lauge
    Hobbs, Charlotte A.
    Laurent, Louise C.
    Knight, Rob
    Hodcroft, Emma B.
    Khan, Kamran
    Fusco, Dahlene N.
    Cooper, Vaughn S.
    Lemey, Phillipe
    Gardner, Lauren
    Lamers, Susanna L.
    Kamil, Jeremy P.
    Garry, Robert F.
    CELL, 2021, 184 (19) : 4939 - +
  • [25] Substantial underestimation of SARS-CoV-2 infection in the United States
    Wu, Sean L.
    Mertens, Andrew N.
    Crider, Yoshika S.
    Nguyen, Anna
    Pokpongkiat, Nolan N.
    Djajadi, Stephanie
    Seth, Anmol
    Hsiang, Michelle S.
    Colford, John M., Jr.
    Reingold, Art
    Arnold, Benjamin F.
    Hubbard, Alan
    Benjamin-Chung, Jade
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [26] Current Testing Strategies for SARS-CoV-2 in the United States
    Cervinski, Mark A.
    Parnas, M. Laura
    Buxton, Barton P.
    Choi, Justin
    Garner, Omai
    Neath, Sean X.
    Zreloff, Jennifer L.
    CLINICAL CHEMISTRY, 2021, 67 (07) : 935 - 940
  • [27] Coordinating SARS-CoV-2 genomic surveillance in the United States
    Nelson, Martha, I
    Thielen, Peter
    VIRUS EVOLUTION, 2021, 7 (02)
  • [28] Immunity to SARS-CoV-2 infection
    Pepper, Marion
    IMMUNOLOGICAL REVIEWS, 2022, 309 (01) : 5 - 7
  • [29] SARS-CoV-2 and Newborn Immunity
    Hellwig, Jennifer P.
    NURSING FOR WOMENS HEALTH, 2022, 26 (01) : 7 - 7
  • [30] The evolving immunity to SARS-CoV-2
    Chen Dong
    National Science Open, 2022, 1 (01) : 5 - 6